Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

FOR46 · FG-3246

Antibody-drug conjugate · Kills target cells, directed at CD46 (membrane cofactor protein) (CD46) · developed by Kyntra Bio

Phase 1/2 Most advanced trial
KYNB Developer
2 Registered trials

What is FOR46?

FOR46 is an antibody-drug conjugate built from a human monoclonal antibody that binds a conformational epitope on CD46, an immune modulatory receptor expressed on certain tumor cells. After binding and internalization, its cytotoxic payload kills the CD46-expressing cells. It is being studied in metastatic castration-resistant prostate cancer and prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
FG-3246
Drug type
Antibody-drug conjugate
Targets
CD46 (membrane cofactor protein) (CD46)
Mechanism
Kills target cells, directed at CD46 (membrane cofactor protein) (CD46)
Therapy area
Oncology
Developer
Kyntra Bio (KYNB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06842498 Phase 2 Metastatic Castration-Resistant Prostate Cancer Recruiting KYNB
NCT05011188 Phase 1/2 Metastatic Castration-resistant Prostate Cancer Active not recruiting KYNB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Castration-resistant Prostate CancerProstate Cancer

Other drugs acting on CD46

More from Kyntra Bio

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the KYNB page.

Follow KYNB, the company behind FOR46

See KYNB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KYNB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.